Gustavo Alva MD DFAPA

Founder and Medical Director of ATP Clinical Research

Education & Training

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
Completed
Phase 2, Phase 3
A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease Start of enrollment: 2017 May 09
Completed
Phase 1, Phase 2
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type Start of enrollment: 2022 Nov 01
RECRUITING
PHASE3
Roles: Contact, Principal Investigator
A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD Start of enrollment: 2021 Jun 21
Completed
Phase 1
Roles: Contact, Principal Investigator
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease Start of enrollment: 2021 Nov 03
COMPLETED
PHASE3
Roles: Principal Investigator, Contact
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease Start of enrollment: 2022 May 12
Active, not recruiting
Phase 2, Phase 3
Roles: Contact
ANC-501 in the Treatment of Adults With Major Depressive Disorder Start of enrollment: 2022 Sep 19
COMPLETED
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

PubMed

Regeneration Biomedical’s Cell Therapy Reduces Tau, Boosts Cognition in Alzheimer’s CasesMay 6th, 2025
(6-Month Paliperidone Palmitate), First and Only Twice-Yearly Treatment for Adults with SchizophreniaSeptember 1st, 2021
Dollars for Docs Mints a MillionaireMarch 11th, 2013
Join now to see all